27.04.2022 – 10:33
Horizon Therapeutics
Dublin (ots)
Horizon Therapeutics plc (Nasdaq: HZNP) today launched its second global innovation competition, the Horizon Awards powered by MIT Solve. With the annual award, the pharmaceutical company and MIT Solve, an initiative of the Massachusetts Institute of Technology (MIT), promote new solutions to improve the quality of life of patients suffering from rare diseases.
The Horizon Prize articulates a unique question designed to encourage entrepreneurs and innovators around the world to develop creative solutions. The task: to solve a problem faced by the more than 400 million people living with a rare disease worldwide. Up to two winners from a network of thousands of innovators, academics and inventors submitting solutions will be awarded a total of $150,000.
This year’s question is “How can we improve the quality of life for people diagnosed with a rare disease?” Corresponding solutions aim, for example, to make information and resources available to patients, to promote community and networking among those affected, to optimize holistic care, to support daily care management, to improve data exchange between service providers and patients, and to address barriers to access to reduce medical care following diagnosis. Participants can here Sign in.
“The Horizon Prize gives innovators from around the world the opportunity to develop potential solutions to improve the lives of people living with rare diseases,” said Tim Walbert, Horizon Chairman, President and CEO. “Living with a rare disease myself, I know that the journey to diagnosis can be long and complex, with a significant impact on the patient’s and their family’s quality of life. With the Horizon Prize, we have created a platform to showcase the breakthrough ideas that necessary support to provide potentially life-changing interventions for people living with rare diseases.”
The first Horizon Prize in 2021 focused on how technology can improve access to care for people living with rare diseases. The winners – Congenica and ThinkGenetic – brought solutions to help patients with diagnosis and access to care.
“The first step in helping patients living with a rare disease is diagnosis. Technology gives us the ability to detect rare diseases at an earlier stage, even in medically underrepresented groups,” said Sandro Morganella, Ph.D. and head of the artificial intelligence department at Congenica. “Funding from the Horizon Prize 2021 allows us to use data in ways that accelerate rare disease diagnosis – contributing to greater health equity around the world.”
About Horizon
Horizon is focused on discovering, developing and commercializing medicines that address the urgent needs of people living with rare, autoimmune and severe inflammatory diseases. Our mission is purposeful: We use scientific expertise and courage to bring clinically meaningful therapies to patients. We believe it takes both science and empathy to change lives. For more information, see www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.
Press contact:
US Media Contact:
Catherine Riedel
Executive Director, Corporate Visibility and Media
[email protected]
Agency contact Germany:
Franziska Schmidt
Account Manager, fischerAppelt, relations GmbH
[email protected]
Original content from: Horizon Therapeutics, transmitted by news aktuell
